Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00138762
Status:
COMPLETED
Last Update Posted:
2012-02-17
First Post:
2005-08-26
Brief Title:
A Study of TorcetrapibAtorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 3 Double Blind Placebo-Controlled Randomized Parallel Group Multicenter Study of the Efficacy Safety and Tolerability of Fixed Combination TorcetrapibAtorvastatin Administered Orally Once Daily for 6 Months Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia Fredrickson Types IIa and IIb
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Torcetrapib project was terminated on December 2 2006 due to safety findings
A study to look at lipid levels in subjects taking the study drug Atorvastatin alone or placebo
A study to look at lipid levels in subjects taking the study drug Atorvastatin alone or placebo
Detailed Description:
For additional information please call 1-800-718-1021
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None